Navid Hafez, MD
Hematology & Oncology · Los Angeles, CANPI 1740505007
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Boehringer Ingelheim International GmbH at 34.3% of the total. Reporting peaked in 2024 at $4,690 and has fallen 54.9% since, to $2,115 in 2025.
Across 31 payments — averaging $435.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$5K
- E.r. Squibb & Sons, L.L.C.$4K
- Pfizer$2K
- Boehringer Ingelheim Pharma GmbH & Co.kg$1K
- F. Hoffmann-la Roche AG$1K
- EMD Serono, Inc.$288
- plus $383 from 5 others
Across 131 payments — averaging $10,814 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tesaro, Inc.$411K
- GSK$210K
- Merck$170K
- Boehringer Ingelheim$161K
- Eli Lilly$133K
- Mirati Therapeutics, Inc.$102K
- plus $230K from 7 others
What the payments were for
- Consulting fees$6,04045%
- Speaking & faculty fees$5,79143%
- Travel & lodging$5854%
- Food & beverage$1,0908%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 8 | $4,632 |
| E.r. Squibb & Sons, L.L.C. | 2 | $3,840 |
| Pfizer | 1 | $2,200 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 2 | $1,159 |
| F. Hoffmann-la Roche AG | 4 | $1,005 |
| EMD Serono, Inc. | 9 | $288 |
| Jazz Pharmaceuticals Inc. | 1 | $127 |
| Galvanize Therapeutics, Inc | 1 | $104 |
| Daiichi Sankyo Inc. | 1 | $85 |
| Genentech USA, Inc. | 1 | $46 |
| Array Biopharma Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered Product$940
- ZEPZELCA$127
- ALIYA SYSTEM$104
How this compares
$13,506 in reported general payments places this provider in the 70th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 11 | $94 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Los Angeles
- Dennis SlamonLos Angeles$3.1M
- George YaghmourLos Angeles$1.9M
- Kevin KellyLos Angeles$894K
- Raghuveer RanganathanLos Angeles$609K
- Matthew RettigLos Angeles$442K
- David BerzLos Angeles$420K
- Gottfried KonecnyLos Angeles$402K
- Antoni RibasLos Angeles$315K
- Edward GaronLos Angeles$301K
- Rahul NaikLos Angeles$297K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.